Targeting bioenergetics is key to counteracting the drug-tolerant state of biofilm-grown bacteria.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractEmbedded in an extracellular matrix, biofilm-residing bacteria are protected from diverse physicochemical insults. In accordance, in the human host the general recalcitrance of biofilm-grown bacteria hinders successful eradication of chronic, biofilm-associated infections. In this study, we demonstrate that upon addition of promethazine, an FDA approved drug, antibiotic tolerance of in vitro biofilm-grown bacteria can be abolished. We show that following the addition of promethazine, diverse antibiotics are capable of efficiently killing biofilm-residing cells at minimal inhibitory concentrations. Synergistic effects could also be observed in a murine in vivo model system. PMZ was shown to increase membrane potential and interfere with bacterial respiration. Of note, antibiotic killing activity was elevated when PMZ was added to cells grown under environmental conditions that induce low intracellular proton levels. Our results imply that biofilm-grown bacteria avoid antibiotic killing and become tolerant by counteracting intracellular alkalization through the adaptation of metabolic and transport functions. Abrogation of antibiotic tolerance by interfering with the cell's bioenergetics promises to pave the way for successful eradication of biofilm-associated infections. Repurposing promethazine as a biofilm-sensitizing drug has the potential to accelerate the introduction of new treatments for recalcitrant, biofilm-associated infections into the clinic.
CitationPLoS Pathog. 2020 Dec 22;16(12):e1009126. doi: 10.1371/journal.ppat.1009126.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
- Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing <i>Pseudomonas aeruginosa</i>.
- Authors: Müsken M, Pawar V, Schwebs T, Bähre H, Felgner S, Weiss S, Häussler S
- Issue date: 2018 Dec
- Conceptual Model of Biofilm Antibiotic Tolerance That Integrates Phenomena of Diffusion, Metabolism, Gene Expression, and Physiology.
- Authors: Stewart PS, White B, Boegli L, Hamerly T, Williamson KS, Franklin MJ, Bothner B, James GA, Fisher S, Vital-Lopez FG, Wallqvist A
- Issue date: 2019 Nov 15
- Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis.
- Authors: Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R
- Issue date: 2002 Nov
- Selective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms.
- Authors: Chua SL, Yam JK, Hao P, Adav SS, Salido MM, Liu Y, Givskov M, Sze SK, Tolker-Nielsen T, Yang L
- Issue date: 2016 Feb 19
- Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
- Authors: Haagensen J, Verotta D, Huang L, Engel J, Spormann AM, Yang K
- Issue date: 2017 Dec 1